Data Availability StatementNot applicable. by establishing a collection of content articles called Methodologies for COVID-19 study and data analysis. As Guest Editors of the Collection, we would like to offer our views concerning methodological difficulties where researchers can help. Statistical challenges of analysing COVID-19 data Statistical models will play a major part in fighting panic with info [2] to avoid or at least minimize the risk of bias which is a common threat in medical and epidemiological studies. In this article, we describe probably the most impressive difficulties for statisticians and data analysts who want to provide?support with this pandemic with their expertise. Getting appropriate medical data of active and closed COVID-19 instances Adrucil kinase activity assay After the outbreak in Wuhan, China (available as open access epidemiological data [3]), medical data can be prospectively collected inside a cohort study design. Merging and cleaning of data from large multi-centre hospitals is crucial and requires sophisticated data management. Artificial intelligence and deep learning algorithm might be suitable to tackle this challenge. Data security, patients consent, ethics statements are essential in non-pandemic situation but they are bureaucratic barriers to get rapid access to clinical data. Pandemic situations require specific handling of these issues and should be discussed on national level. We have to distinguish between active (still hospitalized) and closed (discharged or dead) COVID-19 cases. Case report forms (CRF) for patients with suspected or confirmed COVID-19 are needed to collect and store their data in a standardised way. There are two main initiatives which created protocols for the investigators, the International Severe Acute Respiratory and emerging Infection Consortium (ISARIC) (isaric.tghn.org) and the Lean European Open Survey on SARS-CoV-2 Infected Patients (LEOSS) (leoss.net). In these two initiatives, it is planned that only closed COVID-19 cases are stored. Understanding the complexity of clinical endpoints Endpoints in patients with severe pneumonia are challenging [4]. For COVID-19 patients, the most relevant clinical endpoints are the entrance to intensive treatment, invasive survival and ventilation. Much less relevant endpoints Adrucil kinase activity assay are the want of supportive air. The analysis of the endpoints requires complicated models which grips the time-dependent powerful of the info. Understanding common statistical pitfalls in medical epidemiology Clinical data are extremely time-dependent and need advanced statistical solutions to prevent common pitfalls such as for example selection, length, competing and immortal-time risk bias [5C8]. Developing appropriate evaluation strategies Just as as data ought to be gathered inside a standardised way, data should also be analysed in a standardised way. Statisticians are encouraged to develop suitable analytical strategies to analyse data which Mouse monoclonal to Cytokeratin 5 were collected from standardised protocols (such as ISARIC and LEOSS). Communicating statistical effects and distinguishing them from artefacts Communicating statistics, especially in hectic times during a pandemic, is very challenging. Statisticians are encouraged to support this with clear and transparent statements. Learning from similar studies?about SARS, MERS and influenza A(H1N1pdm09) As in other outbreaks such as SARS in 2002C2003, clinicians are confronted with new diseases for which there is limited knowledge of effective treatment options [9]. Since there is no targeted agent for COVID-19 in such an early outbreak phase, repurposing of available anti-viral drugs and corticosteroids is discussed [9C16], based on?case series [17C23]. Until promising targeted randomized controlled trials exist, it is expected that large observational clinical studies will be performed to evaluate potential treatment effects as it was done, for instance, for SARS, Adrucil kinase activity assay MERS and influenza A(H1N1pdm09) on hospital mortality [24C27]. Observational studies cannot replace randomized controlled trials due to their limited ability to draw causal conclusions. However, they can be used to stimulate further research on the effectiveness of potential treatment options. Updating reporting guidelines for observational studies during a pandemic In pandemic situation, rapid and valid information flow and reporting is crucial. Long-lasting reporting guidelines might do more harm than good. Specific reporting guidelines are needed for Adrucil kinase activity assay pandemic settings. Statistical support for randomized trial The first randomized trial about LopinavirCRitonavir for Adrucil kinase activity assay Covid-19 sufferers was already published.